calcium, magnesium, potassium, and sodium oxybates
Adjunctive therapy • Brands: Xywav
Last reviewed: 2025-12-30
General information
- Class: Adjunctive therapy
- Common US brands: Xywav
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Nighttime CNS depressant (oxybate/GHB; lower-sodium oxybate salts) indicated for cataplexy or excessive daytime sleepiness in narcolepsy (patients 7+), and for idiopathic hypersomnia in adults; Schedule III with boxed warning for respiratory depression and abuse/misuse and dispensed under a REMS (label).
Metabolism & Half‑life
- Metabolism: Non-CYP metabolism (GHB metabolic pathways) (label).
- Half‑life: Single-dose mean 0.66 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- XYWAV (calcium, magnesium, potassium, and sodium oxybates) oral solution prescribing information — DailyMed (2025)
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2021)
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment — Journal of Clinical Sleep Medicine (2021)
- Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy — Sleep (2020)
- Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy — Nature and Science of Sleep (2022)